Item 8.01 Other Events.
On June 15, 2021, Obalon Therapeutics, Inc. (“Obalon”)
announced the anticipated closing of the merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated
January 19, 2021, by and among Obalon, ReShape Lifesciences Inc. (“ReShape”), and Optimus Merger Sub, Inc., a wholly owned
subsidiary of Obalon (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub will merge with and into ReShape with ReShape
surviving as a wholly owned subsidiary of Obalon (the “Merger”). As a result of the Merger, Obalon will be renamed “ReShape
Lifesciences Inc.” (the “Combined Company”) and the shares of common stock of the Combined Company are expected to commence
trading on The Nasdaq Capital Market on June 16, 2021 under the ticker symbol, RSLS. Immediately prior to the closing of the merger, Obalon
will effect a 1-for-3 reverse stock split of its common stock.
A copy of the press release announcing the anticipated closing is filed
as Exhibit 99.1 to this report.
The Nasdaq Stock Market approved the Combined Company’s listing
application subject to the following conditions: (1) the Combined Company must have all financing transactions approved, in advance, by
its independent directors, either acting as a group or by a committee comprised of only independent directors (e.g., the audit committee)
and (2) if the Combined Company is late in filing a required Listing of Additional Shares (LAS) notification form, it will be subject
to immediate delisting.
At a special meeting of Obalon’s stockholders on May 25, 2021,
Obalon’s stockholders approved the issuance of shares of Obalon’s common stock to the stockholders of ReShape and an amendment
to Obalon’s certificate of incorporation to effect the reverse stock split. The joint proxy statement/prospectus filed with the
SEC included important information with respect to the Merger, including risks related to the Combined Company, including that Obalon
and ReShape have operated with a loss and negative cash flows for the entirety of their existence and it is expected the Combined Company
will have to raise significant capital in the future that could be dilutive to stockholders of the Combined Company. Obalon stockholders
should carefully consider the risk factors included there with respect to the Combined Company.
Forward-Looking Statements
Certain statements contained in this filing may
be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements
regarding the merger and the ability to consummate the merger. These forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,”
“anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,”
“future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,”
or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based
on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they
are made, and Obalon undertakes no obligation to update any of them publicly in light of new information or future events. Actual results
could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation:
(1) conditions to the closing of the merger may not be satisfied; (2) the merger may involve unexpected costs, liabilities or delays;
(3) the respective businesses of Obalon and ReShape may suffer as a result of uncertainty surrounding the merger; (4) the outcome of any
legal proceedings related to the merger; (5) Obalon and ReShape may be adversely affected by other economic, business, and/or competitive
factors; (6) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement;
(7) the effect of the announcement of the merger on the ability of Obalon or ReShape to retain and hire key personnel and maintain relationships
with customers, suppliers and others with whom Obalon or ReShape does business, or on Obalon’s or ReShape’s operating results
and business generally; and (8) other risks to consummation of the merger, including the risk that the merger will not be consummated
within the expected time period or at all Additional factors that may affect the future results of Obalon and ReShape are set forth in
their respective filings with the SEC, including each of Obalon’s and ReShape’s most recently filed Annual Report on Form
10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the
SEC’s website at www.sec.gov, specifically under the heading “Risk Factors.” The risks and uncertainties described above
and in Obalon’s most recent Annual Report on Form 10-K and ReShape’s most recent Annual Report on Form 10-K are not exclusive
and further information concerning Obalon and ReShape and their respective businesses, including factors that potentially could materially
affect their respective businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider
these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements.
Readers should also carefully review the risk factors described in other documents that Obalon and ReShape file from time to time with
the SEC. The forward-looking statements in these materials speak only as of the date of these materials. Except as required by law, Obalon
and ReShape assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes
available in the future.